'550 patent would have greater than 75% of its copolymer-1 molecules, on a molar fraction basis, having molecular weights between 2,000 and 20,000 daltons. To establish inherency, Mylan must prove that an attribute is necessarily present each time the prior art is practiced. See Trintec Indus., Inc. v. Top-U.S.A. Corp., 295 F.3d 1292, 1295 (Fed.Cir.2002) (“Inherent anticipation requires that the missing descriptive material is ‘necessarily present,’ not merely probably or possibly present, in the prior art.”). Against this standard, citing a few examples where overlap might occur is legally insufficient to establish that the claimed molar fractions inherently overlap with the molar fractions of the prior art. See also Glaxo Inc. v. Novopharm Ltd., 52 F.3d 1043, 1047-48 (Fed.Cir.1995) (<HOLDING>); W.L. Gore & Assocs. v. Garlock, Inc., 721
holding that the one challenging the patent must in part show that the subject matter of the sale or offer to sell fully anticipated the claimed invention or would have rendered it obvious by its addition to the prior art holding that the second pfaff prong is satisfied despite no actual completion of such software  provided that there is a disclosure that is sufficiently specific to enable a person skilled in the art to write the necessary source code to implement the claimed method holding no inherent disclosure of claimed crystalline polymorph by prior art patent where practicing disclosed prior art method could produce claimed polymorph or alternative unclaimed polymorph holding that after reading the patent a person of skill in the art would not understand the patentee to have invented a generic method where the patent only disclosed one embodiment of it holding that the moving party must show prior art references which alone or combined with other references would have rendered the invention obvious to one of ordinary skill in the art at the time of the invention